Microneedle-Based Nanomotor Cancer Vaccine Combined with Chemotherapy for Synergistic Melanoma Therapy

Abstract

The combination of cancer vaccines and chemotherapy represents a promising therapeutic strategy for tumor treatment. However, the commonly used intravenous injection method often results in limited therapeutic efficacy. To address this challenge, we develop a therapeutic nanomotor cancer vaccine capable of activating immune responses and employ microneedle technology to achieve efficient co-delivery of the nanomotor cancer vaccine and the chemotherapeutic drug doxorubicin (DOX). The nanomotor cancer vaccine is prepared using the desolvation method, with its primary components including the cancer vaccine formed by self-assembly of bovine serum albumin (BSA) and the antigen ovalbumin (OVA), as well as L-arginine (LA) loaded via physical adsorption. These components are co-encapsulated into hyaluronic acid-based microneedles. Upon insertion into the skin, the hyaluronic acid matrix rapidly dissolves, releasing the nanomotor cancer vaccine (OVA/BSA-LA). The LA component enables the nanomotor to specifically target tumor tissues by binding to the highly expressed inducible nitric oxide synthase (iNOS), achieving chemotactic tumor targeting. The nitric oxide (NO) generated during this process induces immunogenic cell death in tumor cells, while the antigen OVA promotes immune cell maturation, activates T cell differentiation, and triggers antitumor immune responses. When combined with DOX, the therapeutic efficacy is further enhanced. In vitro and in vivo experiments demonstrate that the microneedle-based nanomotor cancer vaccine, in combination with chemotherapy, exhibits good efficacy in treating melanoma, offering a promising strategy for melanoma therapy.

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
25 Mar 2025
Accepted
28 Apr 2025
First published
29 Apr 2025

Nanoscale, 2025, Accepted Manuscript

Microneedle-Based Nanomotor Cancer Vaccine Combined with Chemotherapy for Synergistic Melanoma Therapy

Y. Chen, N. Liu, S. Feng, W. Xu, C. Mao and M. Wan, Nanoscale, 2025, Accepted Manuscript , DOI: 10.1039/D5NR01240F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements